AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6118333 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 69
Study 6118333 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam
Number of subjects: 69
Study 31369771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of bivalent HPV vaccine (0.1 to 0.3 mL) at 2-week intervals until complete clearance or for a maximum of 6 sessions
Number of subjects: 44
Study 31369771 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of bivalent HPV vaccine at 0, 1, and 6 months or until complete clearance of warts
Number of subjects: 44
Study 31839083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ESPB with 20 ml of 0.5% ropivacaine
Number of subjects: 60
Study 31839083 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration with 20 ml of 0.5% ropivacaine
Number of subjects: 60
Study 28750676 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke training session for midwifery teams on membrane sweeping
Number of subjects: 2787
Study 26166532 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O inhalation (35%-50%)
Number of subjects: 67
Study 26166532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.50-0.75 mg/kg)
Number of subjects: 67
Study 23334103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT) - repeated administration prior to encoding and retrieval
Number of subjects: 80
Study 23334103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT) - single administration prior to encoding
Number of subjects: 80
Study 23334103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 80
Study 21851876 — intervention group
Group type: EXPERIMENTAL
Intervention: Carperitide infusion (hANP)
Number of subjects: 303
Study 21851876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no carperitide)
Number of subjects: 303
Study 19318693 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-690,550 15 mg twice daily
Number of subjects: 34
Study 19318693 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 34
Study 19263563 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program
Number of subjects: 131
Study 19263563 — intervention group
Group type: COMPARATOR
Intervention: Individual program
Number of subjects: 131
Study 15458808 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing Gum (gum)
Number of subjects: 0
Study 15458808 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (25 g glucose drink)
Number of subjects: 0
Study 15458808 — intervention group
Group type: COMPARATOR
Intervention: Mint Sweet (control for chewing gum)
Number of subjects: 0
Study 15458808 — intervention group
Group type: COMPARATOR
Intervention: Water (control for glucose)
Number of subjects: 0
Study 15458808 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Number of subjects: 0
Study 15458808 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 0
Study 11270304 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% solution applied twice daily for 1 week
Number of subjects: 219
Study 11270304 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% solution applied once daily for 1 week
Number of subjects: 219
Study 11270304 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 1 week
Number of subjects: 219
Study 11270304 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied once daily for 1 week
Number of subjects: 219
Study 9639372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of reduced glutathione (GSH, 50 mg/min)
Number of subjects: 26
Study 9639372 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 26
Study 8080601 — intervention group
Group type: EXPERIMENTAL
Intervention: General health and lifestyle questionnaire with alcohol questions embedded
Number of subjects: 182
Study 8080601 — intervention group
Group type: COMPARATOR
Intervention: Straight alcohol screening questionnaire
Number of subjects: 182
Study 2760247 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of 10 mM flurbiprofen solution in buffered preservative
Number of subjects: 24
Study 2760247 — intervention group
Group type: COMPARATOR
Intervention: Preservative only (control)
Number of subjects: 24
Study 2760247 — intervention group
Group type: EXPERIMENTAL
Intervention: Further 3 irrigations of flurbiprofen at intervals of 2 days
Number of subjects: 24
Study 2760247 — intervention group
Group type: COMPARATOR
Intervention: Buffered preservative solution (control)
Number of subjects: 24
Study 1000999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin (75 mg once daily)
Number of subjects: 48
Study 1000999 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (25 mg 3-times a day)
Number of subjects: 48
Study 1000999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 48
Study 1000999 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 48
Study 30633084 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity
Number of subjects: 658
Study 30633084 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 658
Study 30633084 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation Analysis
Number of subjects: 658
Study 28114610 — intervention group
Group type: EXPERIMENTAL
Intervention: CSI-based intervention
Number of subjects: 20
Study 28114610 — intervention group
Group type: COMPARATOR
Intervention: Traditional intervention
Number of subjects: 20
Study 26717533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/d
Number of subjects: 615
Study 26717533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 6 mg/d
Number of subjects: 615
Study 26717533 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/d
Number of subjects: 615
Study 26717533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 23212806 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily (intensive therapy)
Number of subjects: 0
Study 23212806 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg (standard therapy)
Number of subjects: 0
Study 23212806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (intensive and standard therapy)
Number of subjects: 0
Study 23212806 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing urine albumin concentration
Number of subjects: 0
Study 23212806 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary albumin concentration >300 mcg/ml
Number of subjects: 0
Study 23212806 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 0
Study 21291377 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical biphasic IFN α (1 MU/dose) applied twice daily for two weeks
Number of subjects: 12
Study 21291377 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical biphasic IFN α formulations (5, 15, and 40 MU/g) applied in a patch on healthy volunteers' upper inner arm
Number of subjects: 12
Study 18183564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample sizes ranging from 10 to 40 per group
Number of subjects: 10
Study 18183564 — intervention group
Group type: EXPERIMENTAL
Intervention: General sample size guidelines by type of aim
Number of subjects: 10
Study 16911680 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg q.d. for 6 weeks
Number of subjects: 112
Study 16911680 — intervention group
Group type: COMPARATOR
Intervention: omeprazole 20 mg q.d. for 6 weeks
Number of subjects: 112
Study 14600536 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 60
Study 14600536 — intervention group
Group type: COMPARATOR
Intervention: Placebo transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 60
Study 10874255 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol XL
Number of subjects: 59
Study 10874255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 8840059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1 MAC)
Number of subjects: 120
Study 8840059 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (1 MAC)
Number of subjects: 120
Study 8840059 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-diazepam-nitrous oxide
Number of subjects: 120
Study 1385995 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 20
Study 1385995 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 20
Study 1385995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6702817 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin concentration (HbA1)
Number of subjects: 2040
Study 6702817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose level
Number of subjects: 2040
Study 6702817 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of fasting plasma glucose and HbA1
Number of subjects: 2040
Study 6702817 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glucose one hour post oral glucose load
Number of subjects: 2040
Study 6702817 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glucose two hour post oral glucose load
Number of subjects: 2040
Study 6702817 — intervention group
Group type: EXPERIMENTAL
Intervention: Full three-sample oral glucose tolerance test
Number of subjects: 2040
Study 31950156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal saline irrigations plus omega-3 supplementation
Number of subjects: 110
Study 31950156 — intervention group
Group type: COMPARATOR
Intervention: Nasal saline irrigations
Number of subjects: 110
Study 30813800 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot ACB
Number of subjects: 156
Study 30813800 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour infusion ACB
Number of subjects: 156
Study 30813800 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour infusion ACB
Number of subjects: 156
Study 29174316 — intervention group
Group type: EXPERIMENTAL
Intervention: PIKA vaccine accelerated regimen
Number of subjects: 126
Study 29174316 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine classic regimen
Number of subjects: 126
Study 26249836 — intervention group
Group type: EXPERIMENTAL
Intervention: MALDI‐TOF‐MS with WCX magnetic beads
Number of subjects: 50
Study 26249836 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification model for RA diagnosis
Number of subjects: 50
Study 24311766 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 6-minute walk distance (6MWD) <250 m
Number of subjects: 748
Study 24311766 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week decline in 6MWD >50 m
Number of subjects: 748
Study 24311766 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of 6MWD data in the clinical prediction model
Number of subjects: 748
Study 23033863 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture-control insoles and ankle-foot orthoses (AFOs)
Number of subjects: 24
Study 23033863 — intervention group
Group type: COMPARATOR
Intervention: Ankle-foot orthoses (AFOs) alone
Number of subjects: 24
Study 18620746 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement (Kuraray)
Number of subjects: 18
Study 18620746 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely x Unicem (3M ESPE)
Number of subjects: 18
Study 18620746 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibra (Densply Caulk)
Number of subjects: 18
Study 18620746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with 125 microm aluminum‐oxide (Al(2)O(3)) particles
Number of subjects: 18
Study 18620746 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating using 50 microm Al(2)O(3) particles modified by silica
Number of subjects: 18
Study 18620746 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study 17353866 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone treatment
Number of subjects: 0
Study 15471379 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravenous corticosteroids (1 g) during the six months postpartum
Number of subjects: 42
Study 15471379 — intervention group
Group type: COMPARATOR
Intervention: No treatment after delivery
Number of subjects: 42
Study 11477525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 30
Study 11477525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9574880 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 24
Study 9574880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7891203 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of beta-carotene preparation (30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene)
Number of subjects: 0
Study 2851172 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + cis‐DDP 15 mg/m2 IV weekly
Number of subjects: 95
Study 2851172 — intervention group
Group type: COMPARATOR
Intervention: RT alone (50 Gy)
Number of subjects: 95
Study 29809030 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional arrows
Number of subjects: 58
Study 29809030 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient landmarks
Number of subjects: 58
Study 29809030 — intervention group
Group type: EXPERIMENTAL
Intervention: Map
Number of subjects: 58
Study 29809030 — intervention group
Group type: COMPARATOR
Intervention: Path without additional visual stimuli (control condition)
Number of subjects: 58
Study 27358261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education and increased physical activity for pupils, lifestyle modification for parents, change in food items sold at schools' canteens (18 weeks duration)
Number of subjects: 334
Study 27358261 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention details provided)
Number of subjects: 334
Study 23802641 — intervention group
Group type: EXPERIMENTAL
Intervention: Z350 XT
Number of subjects: 50
Study 23802641 — intervention group
Group type: EXPERIMENTAL
Intervention: Z350 XT with fibers
Number of subjects: 50
Study 23802641 — intervention group
Group type: EXPERIMENTAL
Intervention: P90
Number of subjects: 50
Study 23802641 — intervention group
Group type: EXPERIMENTAL
Intervention: P90 with fibers
Number of subjects: 50
Study 23802641 — intervention group
Group type: COMPARATOR
Intervention: Positive controls (cavities not restored)
Number of subjects: 50
Study 23802641 — intervention group
Group type: COMPARATOR
Intervention: Negative controls (no cavities prepared)
Number of subjects: 50
Study 22692481 — intervention group
Group type: EXPERIMENTAL
Intervention: FATaintPHAT intervention
Number of subjects: 458
Study 20128578 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prednisolone acetate 1% four times daily for 1 week
Number of subjects: 25
Study 20128578 — intervention group
Group type: COMPARATOR
Intervention: No steroid therapy
Number of subjects: 25
Study 17556693 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (extrinsically labeled (13C))
Number of subjects: 20
Study 17556693 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach (intrinsically labeled (15N))
Number of subjects: 20
Study 15008696 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CABG on a beating heart and AAA repair
Number of subjects: 56
Study 15008696 — intervention group
Group type: COMPARATOR
Intervention: CABG on a beating heart
Number of subjects: 56
Study 15008696 — intervention group
Group type: COMPARATOR
Intervention: AAA repair
Number of subjects: 56
Study 11816440 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 268
Study 11816440 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 268
Study 9892280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (annual, 3-monthly, and 6-monthly doses)
Number of subjects: 4072
Study 9892280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4072
Study 8062508 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide infusion at 0.4 pmol min‐1 kg‐1, doubling every 15 min to 6.4 pmol min‐1 kg‐1 for 30 min
Number of subjects: 12
Study 8062508 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide infusion at 0.75 pmol min‐1 kg‐1 for 3 h
Number of subjects: 12
Study 8062508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atrial natriuretic peptide and brain natriuretic peptide infusion for 3 h
Number of subjects: 12
Study 8062508 — intervention group
Group type: COMPARATOR
Intervention: Control infusion (vehicle)
Number of subjects: 12
Study 3376710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hairspray
Number of subjects: 55
Study 3376710 — intervention group
Group type: COMPARATOR
Intervention: Merckofix
Number of subjects: 55
Study 30442868 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH (repository corticotropin injection) 80 U/1.73 m2 administered twice weekly for 6 months, followed by 40 U/1.73 m2 administered twice weekly for 6 months
Number of subjects: 31
Study 30442868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relapse-preventing treatment)
Number of subjects: 31
Study 30442868 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH treatment after dose reduction
Number of subjects: 31
Study 30442868 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH treatment
Number of subjects: 31
Study 27789470 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan plus carboplatin (TC)
Number of subjects: 550
Study 27789470 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (PC, GC, PLDC)
Number of subjects: 550
Study 25608275 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk fabric briefs
Number of subjects: 20
Study 25608275 — intervention group
Group type: COMPARATOR
Intervention: Cotton briefs
Number of subjects: 20
Study 23153742 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium fructoborate
Number of subjects: 166
Study 23153742 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol plus calcium fructoborate
Number of subjects: 166
Study 23153742 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 166
Study 23153742 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care and treatment
Number of subjects: 166
Study 20667439 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative re‐transfusion of mediastinal shed blood (n=39)
Number of subjects: 77
Study 20667439 — intervention group
Group type: COMPARATOR
Intervention: No autotransfusion (discarded mediastinal shed blood, n=38)
Number of subjects: 77
Study 18986531 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily (P-group)
Number of subjects: 150
Study 18986531 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone (NoP-group)
Number of subjects: 150
Study 16293793 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg daily aspirin
Number of subjects: 128
Study 16293793 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg daily aspirin
Number of subjects: 128
Study 16293793 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg daily aspirin
Number of subjects: 128
Study 16293793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 15552351 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional words
Number of subjects: 0
Study 15552351 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorized neutral words
Number of subjects: 0
Study 15552351 — intervention group
Group type: COMPARATOR
Intervention: Random neutral words
Number of subjects: 0
Study 11430539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 U/kg daily of human recombinant GH
Number of subjects: 22
Study 11430539 — intervention group
Group type: COMPARATOR
Intervention: Standard ICU treatment
Number of subjects: 22
Study 9806703 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (2 puffs via metered dose inhaler)
Number of subjects: 68
Study 9806703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 puffs via metered dose inhaler)
Number of subjects: 68
Study 9806703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (smokers and nonsmokers)
Number of subjects: 68
Study 9806703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (albuterol-treated and untreated)
Number of subjects: 68
Study 9806703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (overall)
Number of subjects: 68
Study 8311204 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion anaesthesia (induced with propofol 2.5 mg.kg‐1 and maintained with propofol 12 mg.kg‐1 x h‐1 and 30% O2 in air)
Number of subjects: 27
Study 8311204 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone anaesthesia (induced with thiopentone 4 mg.kg‐1 and maintained with 70% N2O in O2)
Number of subjects: 27
Study 2898636 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg transdermal glyceryl trinitrate (GTN)
Number of subjects: 427
Study 2898636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 31194712 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted, cell culture-derived H5N1 vaccine (7.5 μg full dose)
Number of subjects: 662
Study 31194712 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted, cell culture-derived H5N1 vaccine (3.75 μg half dose)
Number of subjects: 662
Study 28509725 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg/day
Number of subjects: 1333
Study 28509725 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg/day
Number of subjects: 1333
Study 25575895 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological methods (intervention group, 50 cases)
Number of subjects: 150
Study 25575895 — intervention group
Group type: COMPARATOR
Intervention: No psychological intervention (non-intervention group, 50 cases)
Number of subjects: 150
Study 25575895 — intervention group
Group type: COMPARATOR
Intervention: Non-stent group (50 cases)
Number of subjects: 150
Study 23538395 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume, low-intensity training (LTP) for 6 weeks
Number of subjects: 15
Study 23538395 — intervention group
Group type: COMPARATOR
Intervention: High training volume, intensity, and frequency (HTP)
Number of subjects: 15
Study 22014144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 18